A detailed history of Octagon Capital Advisors LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Octagon Capital Advisors LP holds 2,345,075 shares of CNTA stock, worth $37.3 Million. This represents 4.9% of its overall portfolio holdings.

Number of Shares
2,345,075
Previous 2,060,100 13.83%
Holding current value
$37.3 Million
Previous $23.3 Million 9.03%
% of portfolio
4.9%
Previous 3.64%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.04 - $11.87 $2.29 Million - $3.38 Million
284,975 Added 13.83%
2,345,075 $21.2 Million
Q4 2023

Feb 14, 2024

BUY
$5.52 - $8.03 $9.1 Million - $13.2 Million
1,648,172 Added 400.11%
2,060,100 $16.4 Million
Q2 2023

Aug 14, 2023

BUY
$3.68 - $6.9 $58,615 - $109,903
15,928 Added 4.02%
411,928 $2.55 Million
Q1 2023

May 15, 2023

BUY
$3.03 - $4.0 $1.2 Million - $1.58 Million
396,000 New
396,000 $1.52 Million

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.5B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.